Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?
Publication
, Journal Article
Chew, DS; Mark, DB
Published in: JAMA Cardiol
August 1, 2021
Duke Scholars
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
August 1, 2021
Volume
6
Issue
8
Start / End Page
875 / 876
Location
United States
Related Subject Headings
- Humans
- Heart Failure
- Glucosides
- Benzhydryl Compounds
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Chew, D. S., & Mark, D. B. (2021). Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? JAMA Cardiol, 6(8), 875–876. https://doi.org/10.1001/jamacardio.2021.1448
Chew, Derek S., and Daniel B. Mark. “Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?” JAMA Cardiol 6, no. 8 (August 1, 2021): 875–76. https://doi.org/10.1001/jamacardio.2021.1448.
Chew DS, Mark DB. Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? JAMA Cardiol. 2021 Aug 1;6(8):875–6.
Chew, Derek S., and Daniel B. Mark. “Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine?” JAMA Cardiol, vol. 6, no. 8, Aug. 2021, pp. 875–76. Pubmed, doi:10.1001/jamacardio.2021.1448.
Chew DS, Mark DB. Dapagliflozin-Does Cost Make 4-Pillar Heart Failure Therapy Too Herculean a Labor for Medicine? JAMA Cardiol. 2021 Aug 1;6(8):875–876.
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
August 1, 2021
Volume
6
Issue
8
Start / End Page
875 / 876
Location
United States
Related Subject Headings
- Humans
- Heart Failure
- Glucosides
- Benzhydryl Compounds
- 3201 Cardiovascular medicine and haematology